NCT02225561: SICARE

SNPeCPR In Cardiac Arrest REsuscitation

Terminated Phase 3 Last updated 10 January 2020

What this trial tests

Phase 3 trial testing pharmaco- mechanical optimization in Cardiopulmonary Arrest in 1 participant. Terminated before completion.

Timeline

2 January 2015

Primary endpoint
2 July 2017

2 January 2018

Quick facts

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Phase	Phase 3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	1
Start date	2 January 2015
Primary completion	2 July 2017
Estimated completion	2 January 2018
Sites	1 location across France

Drugs / interventions tested

• pharmaco- mechanical optimization
• mechanical optimization only

Conditions studied

• Cardiopulmonary Arrest — all drugs for Cardiopulmonary Arrest →

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

Adults 18 to 75, any sex, with Cardiopulmonary Arrest. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Approximately 50,000 patients are victims of out of hospital cardiac arrest every year in France. Despite cardiopulmonary resuscitation (CPR) and many studies on the topic resuscitation survival after cardiac arrest remains low (1-8%) and has not changed significantly over the past five decades.It has recently been shown that the combination of different non-invasive therapies, cardiopulmonary resuscitation with mechanical CPR with automated compression / decompression and an impedance threshold device, can increase the rate of return of spontaneous circulation and short and long term survival after cardiac arrest.We propose to study a new cardiopulmonary resuscitation called SNPeCPR (Sodium nitroprusside enhanced cardiopulmonary resuscitation), which includes two components:a) a mechanical component: cardiopulmonary resuscitation with automated mechanical external chest compression and an impedance threshold deviceb) a pharmacological component: sodium nitroprusside, an effective arterial vasodilator that decrease vascular resistance, and improve flow in vital organs.Our hypothesis is that SNPeCPR should improve the return of spontaneous circulation rate during cardiac arrest.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.